CD37: The comeback kid

Blood

Volumn 118, Issue 15, 2011, Pages 4007-4008

  Flinn, Ian W ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD37 ANTIGEN; OBINUTUZUMAB; RITUXIMAB; TETRASPANIN;

ANTIGEN EXPRESSION; APOPTOSIS; B LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; LYMPHOMA; NOTE; POINT MUTATION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; T LYMPHOCYTE;

EID: 80054092233     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-372268     Document Type: Note

References (8)

1. Heider KH, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high pro-apoptotic activity for treatment of Bcell malignancies. Blood. 2011;118(15):4159-4168.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.NEngl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
3. Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G. The B cell-associated CD37 antigen (gp40 -52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol. 1988;140(3):905-914. (Pubitemid 18067282)
4. Link MP, Bindl J, Meeker TC, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol. 1986;137(9):3013-3018. (Pubitemid 17177816)
5. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7(8):1027-1038. (Pubitemid 19196525)
6. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10(11):1696-1711. (Pubitemid 23059946)
7. Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110(7):2569-2577. (Pubitemid 47527052)
8. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.